アンチセンスおよびRNAi治療薬の市場規模、シェア、動向分析レポート：技術別、用途別、投与経路別、地域別、セグメント予測、2024年～2030年

アンチセンスおよびRNAi治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、アンチセンスおよびRNAi治療薬の世界市場規模は、2024年から2030年にかけて18.12％のCAGRを記録し、2030年までに146億6,000万米ドルに達すると予測されています。

生物学的ベクターやナノテクノロジーの開拓、新規薬剤分子の上市を含む臨床研究に対する資金援助の増加は、製品開発において重要であり、市場拡大の原動力となっています。

多国籍ヘルスケア組織は、様々な疾患に対する認識を高め、新規治療法の開発を支援しています。研究機関を支援する形で臨床試験に参加する非公開会社も、この分野の拡大を大きく後押しすると予測されます。例えば、2022年3月、Biogen Inc.とIonis Pharmaceuticals, Inc.は、筋萎縮性側索硬化症（ALS）患者を治療するための治験用アンチセンス・オリゴヌクレオチドの第1相試験の結果を発表しました。市場参入企業によるこのような臨床試験の増加は、アンチセンス療法やRNAi療法に基づく製品発売の増加によって市場成長を促進すると予想されます。

アンチセンス療法やRNAi療法は、細胞の成長サイクルに影響を与え、核酸を標的とする様々な疾患の治療に使用することができます。miRNAが遺伝子発現を再生し、タンパク質産生を制御する能力は、結果的に産業の進歩に影響を与え、大きな注目を集めています。米国科学振興協会が2023年7月に発表した論文によると、UMass Chan医科大学とRUSH大学医療センターが開発したアンチセンス療法が、脆弱X症候群の患者から採取した細胞標本でFMRPというタンパク質の産生を回復させるのに有用であることが判明しました。業界におけるこのような進歩は、予測期間中、多くの疾患の治療のためのRNAiとアンチセンス治療薬の需要を促進すると予想されます。

アンチセンスおよびRNAi治療薬市場レポート・ハイライト

• アンチセンスRNA技術は、神経変性疾患や遺伝性疾患のような疾患への幅広い応用により、技術分野で2023年に最大の収益シェアを占めました。
• RNA干渉分野は技術分野で最も急成長が見込まれます。この技術はさらにsiRNAとmiRNAに区分されます。miRNAは細胞の同一性の維持に重要な役割を果たすため、がんの広がりをよりよく理解するために採用されています。
• 用途別では、遺伝病分野が優勢なのは、主要プレーヤーが新規遺伝病治療法の開発にますます注力しているからです。
• アンチセンスおよびRNAi治療薬の世界市場で最大の売上シェアを占めたのは北米でした。同地域の優位性は、同地域に複数のプレーヤーが存在し、業界における地位を強化しようと努力していることに起因します。
• 欧州は、Secarnaのような主要企業が同地域で事業を展開し、拡大していることから、2024年から2030年までの予測期間で最も速い成長を記録すると予測されています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 アンチセンスおよびRNAi治療薬市場の変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• アンチセンスおよびRNAi治療薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 アンチセンスおよびRNAi治療薬市場：技術の推定・動向分析

• 技術市場シェア、2023年と2030年
• セグメントダッシュボード
• 技術展望別の世界のアンチセンスおよびRNAi治療薬市場
• 以下の市場規模、予測および動向分析、2018年から2030年まで
  • RNA干渉
  • アンチセンスRNA

第5章 アンチセンスおよびRNAi治療薬市場：用途の推定・動向分析

• 用途市場シェア、2023年と2030年
• セグメントダッシュボード
• 用途別の世界のアンチセンスおよびRNAi治療薬市場の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで
  • 眼科
  • 心臓代謝障害および腎臓障害
  • 呼吸器疾患
  • がん
  • 神経変性疾患
  • 遺伝性疾患
  • 感染症
  • 皮膚疾患
  • その他

第6章 アンチセンスおよびRNAi治療薬市場：投与経路の推定・動向分析

• 投与経路の市場シェア、2023年と2030年
• セグメントダッシュボード
• 世界のアンチセンスおよびRNAi治療薬市場、投与経路別の見通し
• 以下の市場規模、予測および動向分析、2018年から2030年まで
  • 静脈注射
  • 髄腔内注射
  • 皮下注射
  • その他

第7章 アンチセンスおよびRNAi治療薬市場：地域の推定・動向分析

• 地域市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 市場規模と予測トレンド分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 会社/競合の分類
• ベンダー情勢
  • 主要ディストリビューターとチャネルパートナーのリスト
  • 主要顧客
  • 主要企業シェア分析、2023年
  • Olix Pharmaceuticals
  • GSK plc
  • Sanofi
  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Benitec Biopharma Inc
  • Silence Therapeutics
  • Arbutus Biopharma
  • Bio-Path Holdings Inc
  • Antisense Therapeutics Limited.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 3 North America antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 4 North America antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 5 North America antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 6 U.S. antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 7 U.S. antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 8 U.S. antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 9 Canada antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 10 Canada antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 11 Canada antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 12 Europe antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 13 Europe antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 14 Europe antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 15 Europe antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 16 Germany antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 17 Germany antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 18 Germany antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 19 UK antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 20 UK antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 21 UK antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 22 France antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 23 France antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 24 France antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 25 Italy antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 26 Italy antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 27 Italy antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 28 Spain antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 29 Spain antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 30 Spain antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 31 Denmark antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 32 Denmark antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 33 Denmark antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 34 Sweden antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 35 Sweden antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 36 Sweden antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 37 Norway antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 38 Norway antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 39 Norway antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 44 China antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 45 China antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 46 China antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 47 Japan antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 48 Japan antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 49 Japan antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 50 India antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 51 India antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 52 India antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 53 South Korea antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 54 South Korea antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 55 South Korea antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 56 Australia antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 57 Australia antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 58 Australia antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 59 Thailand antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 60 Thailand antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 61 Thailand antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 62 Latin America antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 63 Latin America antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 64 Latin America surgical ablation market, by application, 2018 - 2030 (USD Million)
• Table 65 Latin America laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
• Table 66 Latin America percutaneous ablation market, by application, 2018 - 2030 (USD Million)
• Table 67 Latin America antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 68 Brazil antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 69 Brazil antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 70 Brazil surgical ablation market, by application, 2018 - 2030 (USD Million)
• Table 71 Mexico antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 72 Mexico antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 73 Mexico surgical ablation market, by application, 2018 - 2030 (USD Million)
• Table 74 Argentina antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 75 Argentina antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 76 Argentina surgical ablation market, by application, 2018 - 2030 (USD Million)
• Table 77 MEA antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
• Table 78 MEA antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 79 MEA antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 80 MEA antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 81 South Africa antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 82 South Africa antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 83 South Africa antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 85 Saudi Arabia antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 87 UAE antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 88 UAE antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 89 UAE antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
• Table 90 Kuwait antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
• Table 91 Kuwait antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
• Table 92 Kuwait antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in Asia Pacific
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in Middle East Africa
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Antisense & RNAi therapeutics market: market outlook
• Fig. 14 Antisense & RNAi therapeutics competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Penetration and growth prospect mapping
• Fig. 18 Industry value chain analysis
• Fig. 19 Antisense & RNAi therapeutics market driver impact
• Fig. 20 Antisense & RNAi therapeutics market restraint impact
• Fig. 21 Antisense & RNAi therapeutics market strategic initiatives analysis
• Fig. 22 Antisense & RNAi therapeutics market: Technology movement analysis
• Fig. 23 Antisense & RNAi therapeutics market: Technology outlook and key takeaways
• Fig. 24 RNA Interference market estimates and forecast, 2018 - 2030
• Fig. 25 Antisense RNA estimates and forecast, 2018 - 2030
• Fig. 26 Antisense & RNAi therapeutics Market: Route of administration movement analysis
• Fig. 27 Antisense & RNAi therapeutics market: Route of administration outlook and key takeaways
• Fig. 28 Intravenous injections market estimates and forecasts, 2018 - 2030
• Fig. 29 Intrathecal injections market estimates and forecasts, 2018 - 2030
• Fig. 30 Subcutaneous injections market estimates and forecasts, 2018 - 2030
• Fig. 31 Other delivery methods market estimates and forecasts, 2018 - 2030
• Fig. 32 Antisense & RNAi therapeutics market: application movement analysis
• Fig. 33 Antisense & RNAi therapeutics market: application outlook and key takeaways
• Fig. 34 Genetic disease market estimates and forecasts, 2018 - 2030
• Fig. 35 Cancer market estimates and forecasts, 2018 - 2030
• Fig. 36 Infectious disease market estimates and forecasts, 2018 - 2030
• Fig. 37 Neurodegenerative disorders market estimates and forecasts, 2018 - 2030
• Fig. 38 Cardiometabolic & renal disorders market estimates and forecasts, 2018 - 2030
• Fig. 39 Ocular disorders market estimates and forecasts, 2018 - 2030
• Fig. 40 Respiratory disorders market estimates and forecasts, 2018 - 2030
• Fig. 41 Skin disorders market estimates and forecasts, 2018 - 2030
• Fig. 42 Others market estimates and forecasts, 2018 - 2030
• Fig. 43 Global antisense & RNAi therapeutics market: Regional movement analysis
• Fig. 44 Global antisense & RNAi therapeutics market: Regional outlook and key takeaways
• Fig. 45 Global antisense & RNAi therapeutics market share and leading players
• Fig. 46 North America market share and leading players
• Fig. 47 Europe market share and leading players
• Fig. 48 Asia Pacific market share and leading players
• Fig. 49 Latin America market share and leading players
• Fig. 50 Middle East & Africa market share and leading players
• Fig. 51 North America
• Fig. 52 North America market estimates and forecasts, 2018 - 2030
• Fig. 53 U.S.
• Fig. 54 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 55 Canada
• Fig. 56 Canada market estimates and forecasts, 2018 - 2030
• Fig. 57 Europe
• Fig. 58 Europe market estimates and forecasts, 2018 - 2030
• Fig. 59 UK
• Fig. 60 UK market estimates and forecasts, 2018 - 2030
• Fig. 61 Germany
• Fig. 62 Germany market estimates and forecasts, 2018 - 2030
• Fig. 63 France
• Fig. 64 France market estimates and forecasts, 2018 - 2030
• Fig. 65 Italy
• Fig. 66 Italy market estimates and forecasts, 2018 - 2030
• Fig. 67 Spain
• Fig. 68 Spain market estimates and forecasts, 2018 - 2030
• Fig. 69 Denmark
• Fig. 70 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 71 Sweden
• Fig. 72 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 73 Norway
• Fig. 74 Norway market estimates and forecasts, 2018 - 2030
• Fig. 75 Asia Pacific
• Fig. 76 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 77 China
• Fig. 78 China market estimates and forecasts, 2018 - 2030
• Fig. 79 Japan
• Fig. 80 Japan market estimates and forecasts, 2018 - 2030
• Fig. 81 India
• Fig. 82 India market estimates and forecasts, 2018 - 2030
• Fig. 83 Thailand
• Fig. 84 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 85 South Korea
• Fig. 86 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 87 Australia
• Fig. 88 Australia market estimates and forecasts, 2018 - 2030
• Fig. 89 Latin America
• Fig. 90 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 91 Brazil
• Fig. 92 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 93 Mexico
• Fig. 94 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 95 Argentina
• Fig. 96 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 97 Middle East and Africa
• Fig. 98 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 99 South Africa
• Fig. 100 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 101 Saudi Arabia
• Fig. 102 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 103 UAE
• Fig. 104 UAE market estimates and forecasts, 2018 - 2030
• Fig. 105 Kuwait
• Fig. 106 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 107 Market share of key market players- Antisense & RNAi therapeutics market

Antisense & RNAi Therapeutics Market Growth & Trends:

The global antisense & RNAi therapeutics market size is expected to reach USD 14.66 billion by 2030, registering a CAGR of 18.12% from 2024 to 2030, according to a new report by Grand View Research, Inc. Developments in biological vectors & nanotechnology and increased financial help for clinical investigations, including the launch of novel drug molecules, are critical in product development and are driving market expansion.

Multinational healthcare organizations raise awareness and assist in the development of novel remedies for a variety of ailments. Private institutes and companies participating in conducting trials through supporting research institutes are predicted to considerably fuel sector expansion. For instance, in March 2022, Biogen Inc. and Ionis Pharmaceuticals, Inc. announced outcomes from the Phase 1 study of an investigational antisense oligonucleotide for treating people with amyotrophic lateral sclerosis (ALS). Such increasing clinical trials through industry participants is anticipated to propel the market growth by rising the product launches based on antisense and RNAi therapies.

Antisense and RNAi therapies can be used to treat various disorders that impact the cell growth cycle and target nucleic acids. The ability of miRNA to regenerate gene expression and regulate protein production, consequently impacting industrial advancement, is receiving much attention. According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome. Such advancements in the industry are expected to propel the demand for RNAi and antisense therapeutics for treating numerous diseases over the forecast period.

Antisense & RNAi Therapeutics Market Report Highlights:

• Antisense RNA technology accounted for the largest revenue share in 2023 in the technology segment due to its wide applications in diseases like neurodegenerative and genetic conditions.
• The RNA interference segment is anticipated to witness the fastest growth in technology. This technology is further segmented into siRNA & miRNA. Due to miRNA's important role in sustaining cell identity, it's being employed to understand cancer spread better.
• Based on application, the genetic disease segment's dominance can be attributed to key players' increasing focus on developing novel genetic disease treatments.
• North America accounted for the largest revenue share in the global antisense and RNAi therapeutics market. The region's dominance can be attributed to the presence of several players in the region and their efforts to strengthen their position in the industry.
• Europe is anticipated to register the fastest growth over the forecast period from 2024 to 2030, owing to key companies like Secarna operating and expanding in the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Route of Administration
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Route of Administration outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Antisense & RNAi Therapeutics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Presence of strong pipeline product portfolio
    • 3.2.1.2. Introduction of technological advancements in drug delivery
    • 3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises
    • 3.2.1.4. Rising collaborations between pharmaceutical companies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Expensive and tedious research programs
    • 3.2.2.2. Delivery of RNAi therapeutics and off-target effects
• 3.3. Antisense & RNAi Therapeutics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Antisense & RNAi Therapeutics Market: Technology Estimates & Trend Analysis

• 4.1. Technology Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Antisense & RNAi Therapeutics Market by Technology Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. RNA Interference
    • 4.4.1.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Antisense RNA
    • 4.4.2.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antisense & RNAi Therapeutics Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2023 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Antisense & RNAi Therapeutics Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Ocular
    • 5.4.1.1. Ocular Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.2. Cardio metabolic & Renal Disorders
    • 5.4.2.1. Cardio metabolic & Renal Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.3. Respiratory Disorders
    • 5.4.3.1. Respiratory Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.4. Cancer
    • 5.4.4.1. Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.5. Neurodegenerative Disorders
    • 5.4.5.1. Neurodegenerative Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.6. Genetic Disorders
    • 5.4.6.1. Genetic Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.7. Infectious Diseases
    • 5.4.7.1. Infectious Diseases Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.8. Skin Diseases
    • 5.4.8.1. Skin Diseases Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4.9. Others
    • 5.4.9.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antisense & RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Market Share, 2023 & 2030
• 6.2. Segment Dashboard
• 6.3. Global Antisense & RNAi Therapeutics Market, by Route of Administration Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.4.1. Intravenous Injections
    • 6.4.1.1. Intravenous Injections Market estimates and forecasts, 2018 to 2030 (USD million)
  • 6.4.2. Intrathecal Injections
    • 6.4.2.1. Intrathecal Injections Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.3. Subcutaneous Injections
    • 6.4.3.1. Subcutaneous Injections Market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.4.4. Others
    • 6.4.4.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Antisense & RNAi Therapeutics Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Target disease prevalence
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Competitive scenario
    • 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Target disease prevalence
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Competitive scenario
    • 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Target disease prevalence
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Competitive scenario
    • 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Target disease prevalence
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Competitive scenario
    • 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Target disease prevalence
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Competitive scenario
    • 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Target disease prevalence
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Competitive scenario
    • 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Target disease prevalence
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Competitive scenario
    • 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Target disease prevalence
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Competitive scenario
    • 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Target disease prevalence
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Competitive scenario
    • 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Target disease prevalence
    • 7.6.8.3. Regulatory framework
    • 7.6.8.4. Competitive scenario
    • 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Target disease prevalence
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Competitive scenario
    • 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Target disease prevalence
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Competitive scenario
    • 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Target disease prevalence
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Competitive scenario
    • 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Target disease prevalence
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Competitive scenario
    • 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Target disease prevalence
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Competitive scenario
    • 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Target disease prevalence
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Competitive scenario
    • 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Target disease prevalence
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Competitive scenario
    • 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Target disease prevalence
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Competitive scenario
    • 7.8.2.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Target disease prevalence
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Competitive scenario
    • 7.8.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Target disease prevalence
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Competitive scenario
    • 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Target disease prevalence
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Competitive scenario
    • 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Target disease prevalence
    • 7.9.3.3. Regulatory framework
    • 7.9.3.4. Competitive scenario
    • 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Target disease prevalence
    • 7.9.4.3. Regulatory framework
    • 7.9.4.4. Competitive scenario
    • 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Olix Pharmaceuticals
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. GSK plc
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Sanofi
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Alnylam Pharmaceuticals, Inc.
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Ionis Pharmaceuticals, Inc.
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Benitec Biopharma Inc
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Silence Therapeutics
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Arbutus Biopharma
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Bio-Path Holdings Inc
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Antisense Therapeutics Limited.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives